A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis

Summary

This is a multicenter, open-label study to evaluate the safety and tolerability and explore the efficacy of FCR001 cell therapy in adults with rapidly progressive Diffuse Cutaneous Systemic Sclerosis (dcSSc) at risk for organ failure.

Timeline

Start

2021-11-24

Primary completion

2026-11

Completion

2027-02

Outcome

Outcome not reported

Stopped: “all clinical development programs terminated by sponsor”

Drugs

Indications